The Fatigue Associated with Depression Questionnaire (FAsD): Responsiveness and responder definition

Quality of Life Research

Volumn 22, Issue 2, 2013, Pages 351-360

  Matza, Louis S ^a   Wyrwich, Kathleen W ^a   Phillips, Glenn A ^b   Murray, Lindsey T ^a   Malley, Karen G ^c   Revicki, Dennis A ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Malley Research Programming Inc   (United States)

Author keywords

Depression; Fatigue; Minimal important difference; Questionnaire; Responder definition; Responsiveness

Indexed keywords

ADULT; AGED; ARTICLE; DEPRESSION; EQUIPMENT; FATIGUE; FEMALE; HUMAN; MALE; MIDDLE AGED; PREDICTIVE VALUE; PREGNANCY; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SICKNESS IMPACT PROFILE; STATISTICS; TREATMENT OUTCOME; COMPLICATION; DEVICES; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; DEPRESSION; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREGNANCY; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 84878386916     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-012-0142-6     Document Type: Article

References (45)

1. Fava, M. (2006). Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol, 20(3 Suppl), 29-34.
2. Kennedy, S. H. (2008). Core symptoms of major depressive disorder: Relevance to diagnosis and treatment. Dialogues Clin Neurosci, 10(3), 271-277.
3. Kurian, B. T.; Greer, T. L.; & Trivedi, M. H. (2009). Strategies to enhance the therapeutic efficacy of antidepressants: Targeting residual symptoms. Expert Review of Neurotherapeutics, 9(7), 975-984.
4. Menza, M.; Marin, H.; & Opper, R. S. (2003). Residual symptoms in depression: Can treatment be symptom-specific? Journal of Clinical Psychiatry, 64(5), 516-523.
5. Pae, C. U.; Lim, H. K.; Han, C.; Patkar, A. A.; Steffens, D. C.; Masand, P. S.; et al. (2007). Fatigue as a core symptom in major depressive disorder: Overview and the role of bupropion. Expert Review of Neurotherapeutics, 7(10), 1251-1263.
6. Papakostas, G. I.; Nutt, D. J.; Hallett, L. A.; Tucker, V. L.; Krishen, A.; & Fava, M. (2006). Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biological Psychiatry, 60(12), 1350-1355.
7. Judd, L. L.; Akiskal, H. S.; Maser, J. D.; Zeller, P. J.; Endicott, J.; Coryell, W.; et al. (1998). Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders, 50(2-3), 97-108.
8. Judd, L. L.; Akiskal, H. S.; Zeller, P. J.; Paulus, M.; Leon, A. C.; Maser, J. D.; et al. (2000). Psychosocial disability during the long-term course of unipolar major depressive disorder. Archives of General Psychiatry, 57(4), 375-380.
9. Nierenberg, A. A.; Husain, M. M.; Trivedi, M. H.; Fava, M.; Warden, D.; Wisniewski, S. R.; et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report. Psychological Medicine, 40(1), 41-50.
10. Thase, M. E.; Simons, A. D.; McGeary, J.; Cahalane, J. F.; Hughes, C.; Harden, T.; et al. (1992). Relapse after cognitive behavior therapy of depression: Potential implications for longer courses of treatment. American Journal of Psychiatry, 149(8), 1046-1052.
11. Kennedy, N.; & Paykel, E. S. (2004). Residual symptoms at remission from depression: Impact on long-term outcome. Journal of Affective Disorders, 80(2-3), 135-144.
12. Ogrodniczuk, J. S.; Piper, W. E.; & Joyce, A. S. (2004). Residual symptoms in depressed patients who successfully respond to short-term psychotherapy. Journal of Affective Disorders, 82(3), 469-473.
13. Paykel, E. S. (1998). Remission and residual symptomatology in major depression. Psychopathology, 31(1), 5-14.
14. Marcus, S. M.; Young, E. A.; Kerber, K. B.; Kornstein, S.; Farabaugh, A. H.; Mitchell, J.; et al. (2005). Gender differences in depression: Findings from the STAR*D study. Journal of Affective Disorders, 87(2-3), 141-150.
15. Maurice-Tison, S.; Verdoux, H.; Gay, B.; Perez, P.; Salamon, R.; & Bourgeois, M. L. (1998). How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. British Journal of General Practice, 48(430), 1245-1246.
16. Tylee, A.; Gastpar, M.; Lepine, J. P.; & Mendlewicz, J. (1999). DEPRES II (Depression Research in European Society II): A patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. International Clinical Psychopharmacology, 14(3), 139-151.
17. Barkham, M.; Rees, A.; Stiles, W. B.; Shapiro, D. A.; Hardy, G. E.; & Reynolds, S. (1996). Dose-effect relations in time-limited psychotherapy for depression. Journal of Consulting and Clinical Psychology, 64(5), 927-935.
18. Nierenberg, A. A.; Keefe, B. R.; Leslie, V. C.; Alpert, J. E.; Pava, J. A.; Worthington, J. J.; I. I. I.; et al. (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. Journal of Clinical Psychiatry, 60(4), 221-225.
19. Swindle, R.; Kroenke, K.; & Braun, L. (Eds.). (2001). Energy and improved workplace productivity in depression. In Investing in Health: The Social and Economic Benefits of Health Care Innovation (Research in Human Capital and Development) (Vol. 14, pp. 323-341). Emerald Group Publishing Limited.
20. Fava, M. (2003). Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. Journal of Clinical Psychiatry, 64(Suppl 14), 30-34.
21. Demyttenaere, K.; De Fruyt, J.; & Stahl, S. M. (2005). The many faces of fatigue in major depressive disorder. International Journal of Neuropsychopharmacology, 8(1), 93-105.
22. Arnold, L. M. (2008). Understanding fatigue in major depressive disorder and other medical disorders. Psychosomatics, 49(3), 185-190.
23. Baldwin, D. S.; & Papakostas, G. I. (2006). Symptoms of fatigue and sleepiness in major depressive disorder. Journal of Clinical Psychiatry, 67(Suppl 6), 9-15.
24. Ferentinos, P. P.; Kontaxakis, V. P.; Havaki-Kontaxaki, B. J.; Paplos, K. G.; & Soldatos, C. R. (2007). The measurement of fatigue in depression. Psychopathology, 40(2), 133-134.
25. Matza, L. S.; Phillips, G. A.; Revicki, D. A.; Murray, L.; & Malley, K. G. (2011). Development and validation of a patient-report measure of fatigue associated with depression. Journal of Affective Disorders, 134(1-3), 294-303.
26. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56-62.
27. Montgomery, S. A.; & Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
28. Rush, A. J.; Giles, D. E.; Schlesser, M. A.; Fulton, C. L.; Weissenburger, J.; & Burns, C. (1986). The inventory for depressive symptomatology (IDS): Preliminary findings. Psychiatry Research, 18(1), 65-87.
29. Mendoza, T. R.; Wang, X. S.; Cleeland, C. S.; Morrissey, M.; Johnson, B. A.; Wendt, J. K.; et al. (1999). The rapid assessment of fatigue severity in cancer patients: Use of the brief fatigue inventory. Cancer, 85(5), 1186-1196.
30. Michielsen, H. J.; De Vries, J.; & Van Heck, G. L. (2003). Psychometric qualities of a brief self-rated fatigue measure: The fatigue assessment scale. Journal of Psychosomatic Research, 54(4), 345-352.
31. Food & Drug Administration. (2009). Guidance for industry - patient-reported outcome measures: Use in medical product development to support labeling claims. Silver Spring, MD: FDA.
32. Leidy, N. K.; Revicki, D. A.; & Geneste, B. (1999). Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health, 2(2), 113-127.
33. Guyatt, G.; Walter, S.; & Norman, G. (1987). Measuring change over time: Assessing the usefulness of evaluative instruments. J Chronic Dis, 40(2), 171-178.
34. Revicki, D.; Hays, R. D.; Cella, D.; & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102-109.
35. Kroenke, K.; & Spitzer, R. L. (2002). The PHQ-9: A new depression diagnostic and severity measure. Psychiatric Annals, 32(9), 1-7.
36. Johns, M. W. (1991). A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep, 14(6), 540-545.
37. Guy, E. (Ed.). (1976). ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.
38. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
39. Kazis, L. E.; Anderson, J. J.; & Meenan, R. F. (1989). Effect sizes for interpreting changes in health status. Medical Care, 27(3 Suppl), S178-S189.
40. Wyrwich, K. W.; Spertus, J. A.; Kroenke, K.; Tierney, W. M.; Babu, A. N.; & Wolinsky, F. D. (2004). Clinically important differences in health status for patients with heart disease: An expert consensus panel report. American Heart Journal, 147(4), 615-622.
41. Wyrwich, K. W.; Tierney, W. M.; & Wolinsky, F. D. (1999). Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. Journal of Clinical Epidemiology, 52(9), 861-873.
42. Wyrwich, K. W. (2004). Minimal important difference thresholds and the standard error of measurement: is there a connection? Journal of Biopharmaceutical Statistics, 14(1), 97-110.
43. Norman, G. R.; Sloan, J. A.; & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582-592.
44. Fleiss, J. L.; Cohen, J.; & Everitt, B. S. (1969). Large sample standard errors of kappa and weighted kappa. Psychological Bulletin, 72(72), 323-327.
45. Wyrwich, K.; Harnam, N.; Revicki, D. A.; Locklear, J. C.; Svedsater, H.; & Endicott, J. (2009). Assessing health-related quality of life in generalized anxiety disorder using the quality of life enjoyment and satisfaction questionnaire. International Clinical Psychopharmacology, 24(6), 289-295.